TMCnet News

InVivo Therapeutics to Present at Upcoming Science and Advocacy Meetings
[October 24, 2016]

InVivo Therapeutics to Present at Upcoming Science and Advocacy Meetings


InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will present at two upcoming science and advocacy meetings.

Alex Aimetti, Ph.D., Sr. Director, Medical Education and Scientific Support, is scheduled to present a keynote presentation in Neuro Engineering at the 2016 Symposium on Biomaterials Science in Iselin, NJ on Tuesday, October 25 at 11:10 AM EDT. The symposium is hosted by the New Jersey Center for Biomaterials. Additional information can be found at http://www.njbiomaterials.org/biomaterials_symposia.htm

Dr. Aimetti is also scheduled to present at the 2016 Working 2 Walk Science & Advocacy Symposium in Minneapolis, MN on Saturday, October 29 at 9:45 AM CDT (News - Alert). The symposium is hosted by Unite 2 Fight Paralysis. Additional information can be found at http://www.u2fp.org/organize/events/working-2-walk/



"I look forward to presenting updates on the company's product development programs at these two important meetings, and also to have the opportunity to meet with the SCI patient community," Dr. Aimetti said.

About the Neuro-Spinal Scaffold™ Implant


Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple (News - Alert) Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company's investigational Neuro-Spinal Scaffold received the 2015 Becker's Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.


[ Back To TMCnet.com's Homepage ]